Humacyte, Inc.
NASDAQ:HUMA
5.26 (USD) • At close November 7, 2024
Overview | Financials
Numbers are in millions (except for per share data and ratios) USD.
| 2023 | 2022 | 2021 | 2020 | 2019 | |
|---|---|---|---|---|---|
| Revenue
| 0 | 1.565 | 1.263 | 1.491 | 6.187 |
| Cost of Revenue
| 76.55 | 8.255 | 0.049 | 8.432 | 75.603 |
| Gross Profit
| -76.55 | -6.69 | 1.214 | -6.941 | -69.416 |
| Gross Profit Ratio
| 0 | -4.275 | 0.961 | -4.655 | -11.22 |
| Reseach & Development Expenses
| 76.55 | 63.26 | 61.341 | 54.078 | 75.603 |
| General & Administrative Expenses
| 23.392 | 22.883 | 21.13 | 12.013 | 16.275 |
| Selling & Marketing Expenses
| -3.002 | 0 | 0 | 0 | 0 |
| SG&A
| 20.39 | 22.883 | 21.13 | 12.013 | 16.275 |
| Other Expenses
| -73.443 | -1.565 | -1.263 | -1.491 | 0 |
| Operating Expenses
| 23.497 | 84.578 | 81.208 | 64.6 | 16.275 |
| Operating Income
| -100.047 | -84.578 | -81.208 | -64.6 | -85.691 |
| Operating Income Ratio
| 0 | -54.043 | -64.298 | -43.327 | -13.85 |
| Total Other Income Expenses Net
| -10.729 | 72.613 | 54.731 | -1.924 | 0.269 |
| Income Before Tax
| -110.776 | -11.965 | -26.477 | -66.524 | -85.422 |
| Income Before Tax Ratio
| 0 | -7.645 | -20.964 | -44.617 | -13.807 |
| Income Tax Expense
| 3.107 | -76.184 | -64.013 | 2.202 | 0 |
| Net Income
| -110.776 | 64.219 | 37.536 | -68.726 | -85.422 |
| Net Income Ratio
| 0 | 41.035 | 29.72 | -46.094 | -13.807 |
| EPS
| -1.07 | 0.62 | 0.94 | -11.8 | -4.25 |
| EPS Diluted
| -1.07 | 0.62 | 0.94 | -11.8 | -4.25 |
| EBITDA
| -89.221 | -160.345 | -136.98 | -55.971 | -78.942 |
| EBITDA Ratio
| 0 | -102.457 | -108.456 | -37.539 | -12.759 |